首页> 美国卫生研究院文献>Porcine Health Management >Vaccination against parasites – status quo and the way forward
【2h】

Vaccination against parasites – status quo and the way forward

机译:针对寄生虫的疫苗接种-现状与未来之路

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although vaccination against various pathogens is integral to health management of swine, vaccines against parasites have not yet been commercialized for the use in pigs. The incentive to develop and commercialize anti-parasitic vaccines in swine are twofold; on the one hand parasitic diseases which are economically important, such as ascarosis and neonatal coccidiosis, could be controlled in a sustainable manner; on the other hand, the transmission of zoonotic parasites, such as Toxoplasma gondii or Cysticercus cellulosae, could be effectively interrupted. Although experimental research indicates that vaccination against a number of porcine parasites is feasible, development and commercialization of potential vaccines so far has been very slow, as our knowledge on the host-parasite interplay in porcine parasitic infections is still very limited. In the light of growing concerns regarding consumer health and antiparasitic drug resistance, however, it is timely to re-direct R&D efforts to the development of biological control options.
机译:尽管针对各种病原体的疫苗接种是猪健康管理不可或缺的一部分,但针对寄生虫的疫苗尚未商业化用于猪中。在猪中开发抗寄生虫疫苗并使之商业化的动机是双重的。一方面,可以可持续地控制经济上重要的寄生虫病,例如a虫病和新生儿球虫病;另一方面,可以有效地阻止人兽共患病寄生虫的传播,例如弓形虫或纤维囊藻。尽管实验研究表明,针对许多猪寄生虫进行疫苗接种是可行的,但由于我们对猪寄生虫感染中宿主-寄生虫相互作用的了解仍然非常有限,迄今为止,潜在疫苗的开发和商业化一直非常缓慢。但是,鉴于对消费者健康和抗寄生虫药耐药性的日益关注,现在应该将研发工作重新定向到生物防治方案的开发上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号